Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
3.990
-0.110 (-2.68%)
At close: Nov 17, 2025, 4:00 PM EST
3.910
-0.080 (-2.01%)
After-hours: Nov 17, 2025, 7:55 PM EST
Camp4 Therapeutics Revenue
Camp4 Therapeutics had revenue of $795.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $3.80M. In the year 2024, Camp4 Therapeutics had annual revenue of $652.00K with 86.29% growth.
Revenue (ttm)
$3.80M
Revenue Growth
+86.29%
P/S Ratio
22.28
Revenue / Employee
$69,127
Employees
55
Market Cap
187.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 652.00K | 302.00K | 86.29% |
| Dec 31, 2023 | 350.00K | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCAMP News
- 3 days ago - CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 11 days ago - CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 6 weeks ago - CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - GlobeNewsWire
- 2 months ago - CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders - GlobeNewsWire
- 3 months ago - CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 6 months ago - CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 6 months ago - CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 7 months ago - CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire